Haven't used Prexa Pharmaceuticals yet?
Ask Trustburn

Ask Trustburn about Prexa Pharmaceuticals

Based on 10 reviews on Trustburn

Based on reviews on this page. Verify anything important with the company directly.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="prexainc-com" data-lang="en"></div>
More widgets

About Prexa Pharmaceuticals

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease.

Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.